-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Corning Jereh Biopharma (Stock code: 9966.
The study (NCT05494918) is an open, multicenter, dose-increasing Phase I clinical study to assess the safety, tolerability, and initial efficacy of JSKN003 in patients with advanced or metastatic solid tumors and to determine the recommended phase II dose (RP2D).
Human epidermal growth factor receptor-2 (HER2) is a member of the epidermal growth factor receptor (EGFR/ErbB) superfamily that regulates tumor proliferation and migration
JSKN003 is an antibody-conjugated drug (bsAb-ADC)
Dr.